LONDON (ShareCast) - (Sharecast News) - Genedrive reported a doubling of revenue and other income to £1m for the year ended 30 June on Friday, from £0.5m a year earlier, as the point-of-care pharmacogenetic testing company shifted from a pre-commercial to a commercial focus.
The AIM-traded firm said its loss after tax narrowed to £5.2m from £7.1m, while cash at the year-end stood at £1.2m and the group remained debt-free.

It completed a £1.23m equity raise in March 2025.

Operational progress was driven by the rollout of its Genedrive CYP2C19 test, which had gained traction following multiple endorsements from national and international clinical bodies, including NICE, which recommended the test as the preferred rapid platform for CYP2C19 genotyping in stroke and transient ischaemic attack.

The testing kit achieved CE marking under the EU's In Vitro Diagnostics Regulation, enabling registrations across Europe, and has been accepted onto the NHS Dynamic Procurement System.

First commercial deployments were now in routine use at Salford Royal Hospital and Peterborough City Hospital, with further studies underway in acute coronary syndrome and broader NHS implementation initiatives.

Genedrive said it was also advancing regulatory plans for US market entry under the FDA's 510(k) submission route, targeted for late in the 2026 financial year, subject to funding.

The company also continued to roll out its MT-RNR1 neonatal test, which received a "conditional" recommendation under NICE's Early Value Assessment pathway and secured around £0.5m in government-backed funding to generate evidence required for full adoption.

The test was now live in 14 UK hospitals, identifying 20 newborns at risk of antibiotic-induced hearing loss since launch, and has been backed by an £0.8m Scottish Government investment for national adoption.

Genedrive also secured international partnerships and is progressing a pilot with the Saudi Ministry of Health under the "Generations Hear" initiative.

The company said it was scaling production capacity, internalising assay manufacturing, and increasing the number of clinical sites using its products, which it expected will support recurring revenue.

It ended November with £0.32m of cash and an average monthly cash burn of about £0.35m. It has agreed heads of terms for a £1m loan from its largest shareholder.

"We are pleased to announce our 2025 final results, which show strong commercial and operational progress and reflect the hard work, dedication and commitment of the genedrive team," said chief executive Gino Miele.

"I would like to extend my thanks to our people, collaborators, shareholders and distributors for their support and I look forward to our Group continuing to grow and lead in emergency care pharmacogenetic testing."

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE